Nutraceutix, Inc. (OTCBB:NUTX) has developed Cobactin E(TM), a proprietary strain of the bacteria Lactobacillus acidophilus that has been shown to inhibit the highly pathogenic Escherichia coli strain O157:H7 in vitro. The Centers for Disease Control estimates that 73,000 cases of infection and 61 deaths in the United States can be attributed to E.